Prothena

Prothena PRTA Stock

$8.16   -0.850543%
Add to favorites
Market Cap
$419.01M
LOW - HIGH [24H]
$8.01 - $8.31
VOLUME [24H]
$340.75K
P/E Ratio
0
Earnings per share
-$0.45
ISIN
IE00B91XRN20
Price   Prediction

Prothena Price Chart

Sorry, that's all we've gotfor now...

Prothena (PRTA) stock price today is 8.16 USD on Tech Market Large (-0.85% on the day). Updated .

Prothena PRTA Financial and Trading Overview

Prothena stock price 8.16 USD
Previous Close 8.23 USD
Open 8.21 USD
Bid 5.94 USD x 200
Ask 10.52 USD x 200
Day's Range 8.01 - 8.31 USD
52 Week Range 7.73 - 11.8 USD
Volume 340.75K USD
Avg. Volume 466.25K USD
Market Cap 419.01M USD
Beta (5Y Monthly) -0.211
PE Ratio (TTM) N/A
EPS (TTM) -0.45 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 21.4 USD

PRTA Valuation Measures

Enterprise Value 153.9M USD
Trailing P/E N/A
Forward P/E -6.580645
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 7.945659
Price/Book (mrq) 1.5584415
Enterprise Value/Revenue 2.918
Enterprise Value/EBITDA -4.082

Trading Information

Prothena Stock Price History

Beta (5Y Monthly) -0.211
52-Week Change -20.39%
S&P500 52-Week Change 13.32%
52 Week High 11.8 USD
52 Week Low 7.73 USD
50-Day Moving Average 8.54 USD
200-Day Moving Average 9.17 USD

PRTA Share Statistics

Avg. Volume (3 month) 466.25K USD
Avg. Daily Volume (10-Days) 408.6K USD
Shares Outstanding 51.35M
Float 34.19M
Short Ratio 14.09
% Held by Insiders 22.96%
% Held by Institutions 90.93%
Shares Short 7.91M
Short % of Float 18.55%
Short % of Shares Outstanding 15.40%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin -45.43%
Operating Margin (ttm) -73.021%
Gross Margin 15.73%
EBITDA Margin -71.48%

Management Effectiveness

Return on Assets (ttm) -7.56%
Return on Equity (ttm) -8.49%

Income Statement

Revenue (ttm) 52.74M USD
Revenue Per Share (ttm) 1 USD
Quarterly Revenue Growth (yoy) -74.29%
Gross Profit (ttm) 8.3M USD
EBITDA -37700000 USD
Net Income Avi to Common (ttm) -23960000 USD
Diluted EPS (ttm) -0.45
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 271.37M USD
Total Cash Per Share (mrq) 5.29 USD
Total Debt (mrq) 6.26M USD
Total Debt/Equity (mrq) 2.33 USD
Current Ratio (mrq) 23.952
Book Value Per Share (mrq) 5.236

Cash Flow Statement

Operating Cash Flow (ttm) -31447000 USD
Levered Free Cash Flow (ttm) -29202500 USD

Profile of Prothena

Country United States
State N/A
City Dublin
Address 77 Sir John Rogerson’s Quay
ZIP D02 VK60
Phone 353 1 236 2500
Website https://www.prothena.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 67

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Q&A For Prothena Stock

What is a current PRTA stock price?

Prothena PRTA stock price today per share is 8.16 USD.

How to purchase Prothena stock?

You can buy PRTA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Prothena?

The stock symbol or ticker of Prothena is PRTA.

Which industry does the Prothena company belong to?

The Prothena industry is Biotechnology.

How many shares does Prothena have in circulation?

The max supply of Prothena shares is 51.35M.

What is Prothena Price to Earnings Ratio (PE Ratio)?

Prothena PE Ratio is now.

What was Prothena earnings per share over the trailing 12 months (TTM)?

Prothena EPS is -0.45 USD over the trailing 12 months.

Which sector does the Prothena company belong to?

The Prothena sector is Healthcare.

Prothena PRTA included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 25136.27 USD —
-0.91
7.74B USD — 24872.41 USD — 25423.09 USD — — 7.74B USD —
us US Tech Biotechnology Total Retu XNBI US 7879.89 USD —
-0.49
— — 7812.06 USD — 7910.07 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 3020.37 USD —
-0.22
— — 2991.33 USD — 3035.56 USD — — — —
us US Tech Global Select Market Com NQGS US 12378.66 USD —
-0.9
— — 12248.6 USD — 12520.36 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Composite Total Return XCMP US 31061.46 USD —
-0.9
— — 30735.41 USD — 31415.87 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2347.16 USD —
+0.24
— — 2326.8 USD — 2354.9 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3748.08 USD —
-0.7
— — 3701.51 USD — 3782.39 USD — — — —
us US Tech Biotechnology NBI US 7211.27 USD —
-0.5
— — 7149.19 USD — 7238.9 USD — — — —
us US Tech Health Care IXHC US 1368.29 USD —
-0.34
— — 1358.68 USD — 1373.65 USD — — — —
$2.19T
Total marketcap
$73.24B
Total volume
BTC 59.41%   •   ETH 10.11%
Dominance
Select currency